May 18, 2022

Calyxt Announces BioFactory™ Pilot Production System Now Operational

ROSEVILLE, Minn., January 6, 2022 /PRNewswire/ — Calixt, Inc. (Nasdaq: CLXT), a plant-based synthetic biotechnology company, today announced that its BioFactory™ pilot production system, installed at the end December 2021is now operational on the site of its headquarters in Minnesota.

Logo (PRNewsfoto/Calyxt, Inc.)

“I am proud of the efforts of our team and our suppliers to reach this milestone on schedule, as it marks an important step in scaling our production. The data we collect and analyze will guide future decisions and will help improve our test cycles and development schedule,” said Michael A. Carr, President and CEO of Calyxt. “We are encouraged by the number of entries from potential customers regarding our technology and the quality of our conversations. we use our screening criteria to determine which compounds to pursue based on customer needs. We look forward to providing further updates on our continued scale and customer acquisition throughout the year.

At October 5, 2021, Calyxt announced the launch of a strategic initiative that focuses the company on engineering synthetic biology solutions for a diverse customer base using its extensive proprietary PlantSpring™ technology platform. The PlantSpring release is integrated with the company’s BioFactory production system, allowing Calyxt to rapidly prototype and produce complex plant-derived compounds without the need for outdoor growing systems.

Calyxt’s proprietary Plant Cell Matrix™ systems have been placed in the BioFactory, where they will be used for pilot production scale testing. The pilot is currently in its testing period, during which the Company will ensure that the system, including its data generation and communication capabilities for artificial intelligence modeling, performs as intended. This is a key step in understanding the scalability of the BioFactory production system.

About the PlantSpring™ Technology Platform and BioFactory™ Production System
Calyxt’s technology platform, PlantSpring, is built on the company’s more than a decade of experience in plant metabolism engineering and includes its scientific insights, proprietary systems, tools and technologies; and a growing set of AIML capabilities. This licensed platform offers innovation through an efficient development process. The process includes identifying breakthrough compounds based on customer needs, designing strategies to reprogram host cells, engineering plant cell metabolism to optimally produce targeted plant-based chemicals, and producing of these target chemicals on a laboratory scale. Calyxt has developed early-stage AIML capabilities in PlantSpring, which enable learning and adaptation of knowledge gained from past activities and can be combined with predictive analytics to quickly prototype and provide feedback, accelerating the time needed to complete the design-engineer-verify development cycle and help mitigate the risk associated with commercial scale-up. As a result, Calyxt believes it can develop biomolecules in plants for its customers at faster speeds than its competitors in the synthetic biology industry. The release of the PlantSpring platform integrates with the company’s new BioFactory production system.

The BioFactory production system is the culmination of the work of Calyxt researchers and will allow the Company to expand its production methods from only outdoor farming systems to also include controlled-environment production systems, based on bioreactors. The BioFactory exploits the potential of plant cells in a multicellular matrix structure and uses nutrient media for its production. The BioFactory exploits multiple cell types and the structures of the multicellular matrix allow the processing of plant-based chemicals of increased complexity compared to those possible using traditional fermentation systems or plant-to-cell cultivation methods. unique. Moreover, the growth rate of the matrix over time should accelerate the production of the compound on a large scale. As a result, Calyxt’s production system is able to unleash the power of plants to produce complex compounds that are finite, sustainably hard to find, and may not be able to be produced using other production methods. . Calyxt has been operating lab scale bioreactors for several months and its first pilot scale bioreactor has been commissioned and is expected to be online by the end of 2021. There may be a range of vessel sizes between initial pilot installation and commercial production. For the transition from pilot to commercialization, the Company’s current plan is to use third parties, called infrastructure partners, for the large-scale production of BioFactory. Due to its production methodology, Calyxt believes the BioFactory has the potential to be one of the most sustainable production systems in any industry.

About Calixt:
Calyxt (Nasdaq: CLXT) is a plant-based synthetic biotechnology company. The company leverages its proprietary PlantSpring™ technology platform to design innovative materials and products for its customers to help them achieve their sustainability goals. Calyxt’s diverse offerings are primarily delivered through its proprietary BioFactory™ production system. For more information, visit

PlantSpring, BioFactory, Plant Cell Matrix and the Calyxt logo are trademarks of Calyxt, Inc. All other marks are the property of their respective owners.

Forward-looking statements:
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. In some instances, you may identify such statements by forward-looking terms such as “anticipates”, “believes “, “continues”, “estimates”, “expects”, “intends”, “may”, “could”, “plans”, “predicts”, “projects”, “should”, ” target”, “will”, or the negative form of these terms and other similar terms. Forward-looking statements in this press release include statements about Calyxt’s pipeline and product development; Calyxt’s ability to use the BioFactory to engineer precursor molecules and convert them into broader chemistries demanded by potential customers; Calyxt’s ability to achieve larger scale production and performance of target molecules; and commercial demand for Calyxt’s synthetic biology solutions. These and other forward-looking statements are predictions and projections of future events and trends based on Calyxt’s current expectations, goals and intentions and are based on current assumptions. Actual results, level of activity, performance or achievements of Calyxt could differ materially from those expressed, implied or anticipated by the forward-looking statements due to a variety of factors, including, but not limited to: the impact of increased competition, including competition from a broader range of synthetic biology businesses; disruptions at Calyxt’s key facilities, including disruptions affecting its BioFactory production system; changes in customer preferences and market acceptance of Calyxt’s products; competition for customers, partners and licensees and the successful execution of development and license agreements; the impact of adverse events during development, including failure to pilot produce compounds or generation of inconsistent data; disruptions to supply chains, including raw material inputs for the Calyxt BioFactory; the impact of changes or increases in supervision and regulation; intellectual property disputes or disputes; the proliferation and continued evolution of new technologies; and other important factors discussed under the heading “Risk Factors” in Calyxt’s Annual Report on Form 10-K and subsequent filings on Form 10-Q or Form 8-K with the Securities and Exchange Commission. United States. Any forward-looking statement made by Calyxt’s management is based solely on information currently available to it at the time and speaks only as of the date such statement is made. Calyxt undertakes no obligation to publicly provide revisions or updates to any forward-looking statement, whether as a result of new information, future developments or otherwise, if circumstances change, except as required by law.


Calyxt Media Contact:

Calyxt Investor Relations Contact:

David Rosen/John Garabo/Michael Barron

Sherri Spear/Cameron Willis

Slang Partners

Slang Partners

(212) 600-1902

(212) 600-1902

[email protected]

[email protected]



View original content to download multimedia:

SOURCECalyxt, Inc.